Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apo T B VfiledCriticalApo T B V
Publication of NZ722167ApublicationCriticalpatent/NZ722167A/en
The present invention discloses that targeting infected cells for killing those infected cells can be achieved by providing a proteinaceous molecule comprising a single polypeptide chain comprising at least two specific binding domains separated by at least one linker further comprising an Fc monomer separated from said at least two specific binding domains by at least one linker, wherein said binding domains are Vh domains which specifically recognize a hepatitis C virus derived peptide in the context of MHC-1. More generally, the present invention relates to proteinaceous molecules comprising multiple recombinant antibody-fragments assembled at the DNA level into a single chain, which specifically bind hepatitis C virus derived peptide in the context of MHC-1. In addition, the invention relates to methods of diagnosing and treatment of infectious disease using these recombinant single-chain polypeptides.
Isolated antigen binding protein that binds yl-23, comprising at least both a heavy chain and light chain variable region comprising mutated cdrs; nucleic acid, vector and host cell encoding it; pharmaceutical composition; and its use to treat il-23 associated diseases in a patient.